切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2009, Vol. 03 ›› Issue (06) : 499 -502. doi: 10.3877/cma.j.issn.1674-0793.2009.06.013

论著

乳腺癌肉瘤的临床特点与病理生物学特性
张毅1,(), 曹明智1   
  1. 1.266003 青岛大学医学院附属医院
  • 收稿日期:2009-03-23 出版日期:2009-12-01
  • 通信作者: 张毅

Clinical characteristic of breast carcinosarcoma in pathology and biology

Yi ZHANG1,(), Ming-zhi Cao1   

  1. 1.Department of General Surgery, The Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, China
  • Received:2009-03-23 Published:2009-12-01
  • Corresponding author: Yi ZHANG
引用本文:

张毅, 曹明智. 乳腺癌肉瘤的临床特点与病理生物学特性[J/OL]. 中华普通外科学文献(电子版), 2009, 03(06): 499-502.

Yi ZHANG, Ming-zhi Cao. Clinical characteristic of breast carcinosarcoma in pathology and biology[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2009, 03(06): 499-502.

目的

探讨乳腺癌肉瘤的临床特点与病理生物学特性,为以手术为主的综合性治疗提供重要依据。

方法

回顾性分析经手术和病理学证实26例乳腺癌肉瘤的临床资料,并将30例乳腺癌作为免疫表型的对照组,研究该肿瘤的临床特点和病理生物学特性。

结果

乳腺癌肉瘤中癌成分>50%者占61.54%,同侧腋淋巴结癌转移率达30.77%;肉瘤成分>50%者占38.46%,同侧腋淋巴结内未见癌转移。免疫组化癌成分中EMA和CK阳性率均96.15%,P53、ER和PR阳性率分别为53.85%、61.54%和30.77%,Vimentin和S100阳性率分别为19.23%和15.38%。肉瘤成分中Vimentin和S100阳性率分别为96.15%和88.46%,EMA、CK、ER、PR和P53阳性率分别为19.23%、11.54%、7.69%、3.85%和3.85%。P53、ER、PR、Vimentin和S100与对照组差异有统计学意义(P<0.05);EMA和CK与对照组差异无统计学意义。

结论

乳腺癌肉瘤是由上皮和间叶成分混合而成的恶性肿瘤,因其成分不同,免疫表型差异较大。它具有双重侵袭性和极易复发的生物学特性,手术和放化疗是最佳的综合性治疗方法。

Objective

To investigate the clinical pathological and biology features of breast carcinosarcoma, find some important information for integrate surgical treatment.

Methods

The histopathology and immunophenotype of 26 cases breast carcinosarcoma and 30 cases breast cacinoma were reviewed.Clinical data such as operation,pathological and biology features were studied.

Results

In all cases,61.54%of all cases were composed of more than half of carcinoma, with 30.77% of that had axillary lymph nodes metastatic tumor. 38.46%were composed of more than half of sarcoma,30.77%had axillary lymph nodes metastatic tumor with no axillary lymphnodesmetastatictumor.ImmunohistochemistryresultsshowedpositiverateofEMA,CK,P53,ER,PR in carcinoma issues were 96.15%,96.15%,53.85%,61.54%and 30.77%.And that of Vimentin and S100 were 19.23%and 15.38%,respectively.The positive rate of EMA,CK,P53,ER,PR in sarcoma issues were 19.23%,11.54%,7.69%,3.85%,3.85%.And that of Vimentin and S100 were 96.15%and 88.46%,respectively.There was no statistical difference between two groups in the terms of EMA and CK.

Conclusions

Primary carcinosarcoma of the breastis fountainhead blend of malignant epithelium and phyllodes tumor,which is a sort of invasive malignant tumor with high recurrence.Integrate treatmentmay be effective.

表1 26 例乳腺癌肉瘤成分免疫组化阳性表达情况[例(%)]
表2 两组患者免疫组化阳性表达指标比较[n(%)]
1
沈镇宙,邵志敏.乳腺肿瘤学.上海:上海科学技术出版社,2005:156-170.
2
侯德法,孟刚,郝大海.肉瘤样癌形态学及免疫组化观察.安徽医科大学学报,2008,43(6):627-630.
3
Confavreux C, Lurkin A, Mitton N, et al. Sarcomas and malignant phyll odes tumors of the breast aretrospective study. Eur J Cancer, 2006, 42(16):2715-2721.
4
马日海,汪建初,蒲涧.乳腺癌肉瘤10 例临床诊治分析.实用医学杂志,2007,23(10):1521.
5
Gogas J,Kouskos E,Markopoulos C,et al.Carcinosarcoma of the bre ast:report of two cases.Eur J Gynaecol Oncol,2003,24(1):93-95.
6
Tavassoli FA, Devilee P. World Health Organization classification of tu mours.Pathology and genetics of tumours of the breast and female genital organs.Lyon:IARC,2003:40-41.
7
Poynter N, Del man K, Folpe AL, et al. National surgical peatterns of care: Axillary staging of breast sarcomas. Proceedings of the 48th Annual ASTRO Meeting.2006,66:718.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[3] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[7] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[8] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[9] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[10] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[11] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[12] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[13] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[14] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[15] 王曦娅, 尹弘青, 丁伟, 徐滨, 于海源, 马东升, 邵军. 桥本背景下甲状腺乳头状癌多参数分析预测大容量淋巴结转移[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 548-554.
阅读次数
全文


摘要